L. Kjems

发表

Validation of methods for measurement of insulin secretion in humans in vivo.

R. Bergman, S. Madsbad, A. Vølund, 2000, Diabetes.

Signal Epitopes in the Three‐Dimensional Structure of Neuropeptide Y

T. Schwartz, L. Kjems, J. Krstenansky, 1990, Annals of the New York Academy of Sciences.

Pulsatile insulin secretion by human pancreatic islets.

P. Butler, J. Veldhuis, Michael L. Johnson, 2002, The Journal of clinical endocrinology and metabolism.

Decrease in beta-cell mass leads to impaired pulsatile insulin secretion, reduced postprandial hepatic insulin clearance, and relative hyperglucagonemia in the minipig.

M. Straume, P. Butler, J. Veldhuis, 2001, Diabetes.

Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes.

N. Porksen, P. Kao, P. Butler, 2000, American journal of physiology. Endocrinology and metabolism.

Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function[S]

D. Rader, S. Reddy, M. Navab, 2011, Journal of Lipid Research.

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.

J. Holst, S. Madsbad, A. Vølund, 2003, Diabetes.

Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial

J. Rosenstock, J. Buse, M. Baron, 2017, Diabetes Care.

No influence of proinsulin and insulin on plasma levels of plasminogen activator inhibitor type 1 and tissue plasminogen activator in young women before and during intake of contraceptive steroids.

J. Jespersen, L. Kjems, K. Petersen, 1996, Metabolism: clinical and experimental.

Lack of stimulation of 24-hour growth hormone release by hypocaloric diet in obesity.

N. Skakkebaek, A. Juul, J. Hilsted, 1995, The Journal of clinical endocrinology and metabolism.

Pharmacokinetics and Pharmacodynamics of Vildagliptin in Healthy Chinese Volunteers

Yan-Ling He, Dongyang Liu, Ji Jiang, 2009, Journal of clinical pharmacology.

Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist

J. Holst, Yan-Ling He, J. Foley, 2016, Diabetes.

Do oscillations of insulin secretion occur in the absence of cytoplasmic Ca2+ oscillations in beta-cells?

M. Ravier, J. Henquin, J. Jonas, 2002, Diabetes.

Highly sensitive enzyme immunoassay of proinsulin immunoreactivity with use of two monoclonal antibodies.

C. Binder, M. Røder, L. Kjems, 1993, Clinical chemistry.

Insulin secretion rates estimated by two mathematical methods in pancreas-kidney transplant recipients.

S. Madsbad, C. Binder, A. Vølund, 1998, The American journal of physiology.

Insulin secretion rates estimated by two mathematical methods in pancreas-kidney transplant recipients.

S. Madsbad, C. Binder, A. Vølund, 1998, American journal of physiology. Endocrinology and metabolism.

Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study

J. Rosenstock, R. Henry, M. Baron, 2018, Diabetes Care.

Development of the Patient- and Observer-Reported PRUCISION Instruments to Assess Pruritus and Sleep Disturbance in Pediatric Patients with Cholestatic Liver Diseases

C. Gwaltney, Stephanie E. Bean, L. Kjems, 2022, Advances in Therapy.

Validation of the PRUCISION Instruments in Pediatric Patients with Progressive Familial Intrahepatic Cholestasis

C. Gwaltney, C. Ivanescu, L. Kjems, 2022, Advances in Therapy.

Effects of short-term caloric restriction on circulating free IGF-I, acid-labile subunit, IGF-binding proteins (IGFBPs)-1-4, and IGFBPs-1-3 protease activity in obese subjects.

A. Juul, J. Hilsted, M. H. Rasmussen, 2006, European journal of endocrinology.

Monokine Antagonism Is Reduced in Patients With IDDM

F. Pociot, J. Nerup, L. Shapiro, 1994, Diabetes.

Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial.

Richard J. Thompson, L. D’Antiga, R. Houwen, 2022, The lancet. Gastroenterology & hepatology.

Skeletal muscle mitochondrial capacity and insulin resistance in type 2 diabetes.

K. Conley, Steven R Smith, C. Moro, 2011, The Journal of clinical endocrinology and metabolism.

Carriers of the TCF7L2 rs7903146 TT genotype have elevated levels of plasma glucose, serum proinsulin and plasma gastric inhibitory polypeptide (GIP) during a meal test

T. Hansen, O. Pedersen, N. Grarup, 2010, Diabetologia.

Postprandial suppression of glucagon secretion depends on intact pulsatile insulin secretion: further evidence for the intraislet insulin hypothesis.

Johannes D Veldhuis, P. Butler, J. Veldhuis, 2006, Diabetes.

EP1231: ODEVIXIBAT THERAPY IMPROVES CLINICALLY MEANINGFUL ENDPOINTS IN CHILDREN WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS: DATA FROM THE PEDFIC 1 AND PEDFIC 2 TRIALS

L. D’Antiga, H. Verkade, S. Karpen, 2022, Gastroenterology.

EP1233: LONG-TERM TREATMENT WITH ODEVIXIBAT IMPROVES MULTIPLE SLEEP PARAMETERS IN PATIENTS WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS: A POOLED RESPONDER ANALYSIS FROM THE PHASE 3 PEDFIC STUDIES

P. Horn, P. Calvo, C. Mack, 2022, Gastroenterology.

EP1230: EFFICACY AND SAFETY OF ODEVIXIBAT IN CHILDREN WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS WITH PRIOR PARTIAL EXTERNAL BILIARY DIVERSION

Richard J. Thompson, B. Kamath, P. Horn, 2022, Gastroenterology.

L2 Efficacy and safety outcomes with odevixibat in children with progressive familial intrahepatic cholestasis due to deficiencies in multidrug resistance protein 3 (PFIC type 3) or myosin 5B (PFIC type 6)

L. Kjems, H. Özen, B. Dalgıç, 2022, Liver.

PMU62 Improved Quality of Life in Children With Progressive Familial Intrahepatic Cholestasis Following 24 Weeks of Treatment With Odevixibat, an Ileal Bile Acid Transporter Inhibitor: Results From the Phase 3 PEDFIC 1 Study

W. Hardikar, L. Kjems, E. Lainka, 2021 .

Serum growth hormone-binding protein in obesity: effect of a short-term, very low calorie diet and diet-induced weight loss.

K. Ho, J. Hilsted, M. H. Rasmussen, 1996, The Journal of clinical endocrinology and metabolism.

35th Annual meeting of the European Association for the Study of Diabetes. Brussels, Belgium, 28 September-2 October, 1999. Abstracts.

Thomas J. Smith, B. M. Rasmussen, V. C. Phan, 1999, Diabetologia.

Improved postprandial glycaemic controls with insulin Aspart in type 2 diabetic patients treated with insulin

K. Birkeland, S. Madsbad, K. Hanssen, 2000, Acta Diabetologica.

Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis

Richard J. Thompson, L. D’Antiga, R. Houwen, 2023, JHEP reports : innovation in hepatology.

An unusual type of familial lipodystrophy.

M. H. Rasmussen, L. Kjems, K. Johansen, 1995, The Journal of clinical endocrinology and metabolism.

Long-term administration of intravenous Trappsol® Cyclo™ (HP-β-CD) results in clinical benefits and stabilization or slowing of disease progression in patients with Niemann-Pick disease type C1: Results of an international 48-week Phase I/II trial

Sharon H. Hrynkow, M. Paucar, R. Spiegel, 2023, Molecular genetics and metabolism reports.

Quantification of beta-cell function during IVGTT in Type II and non-diabetic subjects: assessment of insulin secretion by mathematical methods

S. Madsbad, A. Vølund, L. Kjems, 2001, Diabetologia.